Natixis Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $223M | Sell |
448,631
-105,393
| -19% | -$46.7M | 0.25% | 82 |
|
|
2026
Q1 | $247M | Buy |
554,024
+26,160
| +5% | +$12.2M | 0.34% | 64 |
|
|
2025
Q4 | $239M | Sell |
527,864
-9,330
| -2% | -$4.02M | 0.34% | 53 |
|
|
2025
Q3 | $210M | Sell |
537,194
-3,336
| -0.6% | -$1.39M | 0.31% | 65 |
|
|
2025
Q2 | $241M | Sell |
540,530
-60,657
| -10% | -$28M | 0.38% | 46 |
|
|
2025
Q1 | $291M | Buy |
601,187
+43,543
| +8% | +$20.3M | 0.54% | 28 |
|
|
2024
Q4 | $225M | Buy |
557,644
+95,758
| +21% | +$44.4M | 0.42% | 43 |
|
|
2024
Q3 | $215M | Buy |
461,886
+25,301
| +6% | +$12.2M | 0.42% | 44 |
|
|
2024
Q2 | $205M | Buy |
436,585
+104,522
| +31% | +$45.4M | 0.44% | 38 |
|
|
2024
Q1 | $139M | Buy |
332,063
+12,587
| +4% | +$5.32M | 0.32% | 67 |
|
|
2023
Q4 | $130M | Buy |
319,476
+266
| +0.1% | +$98.3K | 0.34% | 63 |
|
|
2023
Q3 | $111M | Sell |
319,210
-153,998
| -33% | -$53.9M | 0.34% | 63 |
|
|
2023
Q2 | $167M | Buy |
473,208
+10,220
| +2% | +$3.44M | 0.51% | 32 |
|
|
2023
Q1 | $146M | Sell |
462,988
-4,344
| -0.9% | -$1.3M | 0.5% | 35 |
|
|
2022
Q4 | $135M | Sell |
467,332
-41,088
| -8% | -$12.5M | 0.51% | 33 |
|
|
2022
Q3 | $147M | Sell |
508,420
-95,775
| -16% | -$27.6M | 0.62% | 19 |
|
|
2022
Q2 | $170M | Sell |
604,195
-66,323
| -10% | -$17.8M | 0.75% | 13 |
|
|
2022
Q1 | $175M | Buy |
670,518
+2,716
| +0.4% | +$645K | 0.67% | 18 |
|
|
2021
Q4 | $147M | Buy |
667,802
+51,094
| +8% | +$9.94M | 0.56% | 30 |
|
|
2021
Q3 | $112M | Buy |
616,708
+407,937
| +195% | +$79.6M | 0.46% | 43 |
|
|
2021
Q2 | $42.1M | Buy |
208,771
+37,665
| +22% | +$7.88M | 0.2% | 125 |
|
|
2021
Q1 | $36.8M | Buy |
171,106
+30,638
| +22% | +$6.73M | 0.19% | 135 |
|
|
2020
Q4 | $33.2M | Sell |
140,468
-69,574
| -33% | -$16M | 0.19% | 129 |
|
|
2020
Q3 | $57.2M | Buy |
210,042
+13,085
| +7% | +$3.61M | 0.36% | 55 |
|
|
2020
Q2 | $57.2M | Buy |
196,957
+40,730
| +26% | +$11M | 0.38% | 51 |
|
|
2020
Q1 | $37.2M | Buy |
156,227
+16,901
| +12% | +$3.88M | 0.3% | 71 |
|
|
2019
Q4 | $30.5M | Buy |
139,326
+1,060
| +0.8% | +$215K | 0.22% | 100 |
|
|
2019
Q3 | $23.4M | Buy |
138,266
+8,660
| +7% | +$1.53M | 0.19% | 131 |
|
|
2019
Q2 | $23.8M | Buy |
129,606
+8,585
| +7% | +$1.5M | 0.19% | 119 |
|
|
2019
Q1 | $22.3M | Sell |
121,021
-8,150
| -6% | -$1.51M | 0.19% | 116 |
|
|
2018
Q4 | $21.4M | Buy |
129,171
+2,881
| +2% | +$499K | 0.21% | 100 |
|
|
2018
Q3 | $24.3M | Buy |
126,290
+10,203
| +9% | +$1.82M | 0.21% | 95 |
|
|
2018
Q2 | $19.7M | Buy |
116,087
+36,853
| +47% | +$5.71M | 0.19% | 115 |
|
|
2018
Q1 | $12.9M | Sell |
79,234
-21
| -0% | -$3.43K | 0.13% | 175 |
|
|
2017
Q4 | $11.9M | Sell |
79,255
-2,882
| -4% | -$427K | 0.12% | 203 |
|
|
2017
Q3 | $12.5M | Sell |
82,137
-3,388
| -4% | -$510K | 0.13% | 177 |
|
|
2017
Q2 | $11M | Sell |
85,525
-8,551
| -9% | -$1.03M | 0.12% | 201 |
|
|
2017
Q1 | $10.3M | Buy |
94,076
+931
| +1% | +$82K | 0.11% | 212 |
|
|
2016
Q4 | $6.86M | Buy |
93,145
+23,247
| +33% | +$1.89M | 0.08% | 304 |
|
|
2016
Q3 | $6.1M | Buy |
69,898
+6,663
| +11% | +$630K | 0.08% | 319 |
|
|
2016
Q2 | $5.44M | Sell |
63,235
-1,620
| -2% | -$140K | 0.08% | 339 |
|
|
2016
Q1 | $5.16M | Buy |
64,855
+14,372
| +28% | +$1.3M | 0.08% | 327 |
|
|
2015
Q4 | $6.35M | Buy |
50,483
+1,814
| +4% | +$219K | 0.1% | 245 |
|
|
2015
Q3 | $5.07M | Buy |
48,669
+4,234
| +10% | +$544K | 0.09% | 312 |
|
|
2015
Q2 | $5.49M | Buy |
44,435
+503
| +1% | +$63.4K | 0.09% | 304 |
|
|
2015
Q1 | $5.18M | Buy |
43,932
+820
| +2% | +$98.2K | 0.09% | 331 |
|
|
2014
Q4 | $5.12M | Sell |
43,112
-837
| -2% | -$94.3K | 0.1% | 322 |
|
|
2014
Q3 | $4.94M | Buy |
43,949
+4,188
| +11% | +$399K | 0.1% | 320 |
|
|
2014
Q2 | $3.77M | Buy |
39,761
+1,543
| +4% | +$108K | 0.05% | 521 |
|
|
2014
Q1 | $2.7M | Buy |
38,218
+3,517
| +10% | +$279K | 0.04% | 565 |
|
|
2013
Q4 | $2.58M | Sell |
34,701
-937
| -3% | -$65.3K | 0.04% | 556 |
|
|
2013
Q3 | $2.7M | Sell |
35,638
-3,525
| -9% | -$281K | 0.05% | 511 |
|
|
2013
Q2 | $3.14M | Buy |
+39,163
| New | +$2.88M | 0.06% | 468 |
|
Other funds holding VRTX
Natixis Advisors's VRTX Position: Q2 2026 in Review
Natixis Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 19% in Q2 2026, selling an estimated $46.7M and leaving 448,631 shares worth $223M. The position accounts for 0.25% of the portfolio, ranked #82.
Natixis Advisors first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $291M in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Natixis Advisors held 448,631 shares of Vertex Pharmaceuticals worth $223M as of Q2 2026.
- Natixis Advisors sold 105,393 Vertex Pharmaceuticals shares in Q2 2026, an estimated $46.7M.
- Vertex Pharmaceuticals made up 0.25% of Natixis Advisors's portfolio in Q2 2026, its #82 holding.
- Natixis Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Natixis Advisors's Vertex Pharmaceuticals position peaked at $291M in Q1 2025.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.